CNETS Canada is committed to improving the quality of life and survival for NET patients across Canada and in support of this vision introduced a new Research Funding Framework in 2016. The CNETS Canada Neuroendocrine Tumour Research Grant, provides grant-in-aid for two projects up to a maximum of $40,000 per project, per calendar year.
The NET research funding priorities were determined through consultation with the NET patient community, and input from CNETS Canada’s Scientific and Medical Advisory Board (SMAB). To be eligible for the 2017 NET Research Grant, it was determined that the project must be a clinical trial or a clinical or fundamental research project (including animal or cellular models) to examine issues relevant for the diagnosis and treatment of Neuroendocrine tumors (NETs).
This year, we received eight applications for NET cancer research projects in Canada, an excellent level of interest and reflects the growing number of clinicians and centres with a focus on NET cancers. The review and recommendation process was carried out by a Grant Review Committee, chaired by CNETS Canada Scientific & Medical Advisory Board Co-Chairs, Dr. Girish Shah and Dr. Jean-Luc Urbain. Additional panel members included one patient and three members of the CNETS Canada Scientific & Medical Advisory Board, in addition to an oncologist and a radiologist from within the Canadian NET community. Proposals were assessed on medical and scientific merits and overall value proposition and the ultimate granting decision was made by the CNETS Canada Board of Directors.
CNETS Canada is delighted to announce the two 2017 Neuroendocrine Tumour Research Grant Recipients, focusing on the areas of lung NETs and immunotherapy for high grade NEC patients.
CNETS Canada congratulates the successful applicants and further acknowledges the hard work, dedication and passion of all applicants.
These funding decisions are for information only. Only a fully executed letter of agreement will constitute the official record.